CONNECT WITH US
HealthTech

HealthTech

STAT+: OpenEvidence’s JAMA paper leaves open questions

STAT — Health Tech logo

Published on

Add as a preferred source on Google
STAT+: OpenEvidence’s JAMA paper leaves open questions

Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lying

STAT Plus: Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds

STAT Plus: Does Isomorphic Labs have what it takes to revolutionize drugmaking?

STAT Plus: How the No Surprises Act’s nonprofit arbitrators are operating like 'mini gods' and getting rich doing it

STAT Plus: Does Isomorphic Labs have what it takes to revolutionize drugmaking?

STAT Plus: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug

I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lying



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.